, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
August 15, 2017 Subject: MD&A for the financial statements of the 2nd quarter of fiscal year 2017 ended as of June 30, 2017 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company
year. For the period of nine months of the fiscal year 2017, the Company's financing cost was 42.48 Million Baht, increased by 32.67 Million Baht, or up by 333.03% from the previous year. The result was
) AAPICO HITECH PUBLIC COMPANY LIMITED Ref No: AH 01032020 March 3, 2020 Subject: Management Discussion & Analysis (MD&A) for the financial statements of fiscal year 2019 ended as of December 31, 2019 To
quarter of fiscal year 2019 ended as of June 30, 2019 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company Limited (“the Company”) would like to clarify the consolidated financial
No: AH 03052021 May 17, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 1st quarter of fiscal year 2021 ended as of March 31, 2021 To: The President The Stock
No: AH 02112021 November 12, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 3rd quarter of fiscal year 2021 ended as of September 30, 2021 To: The President
No: AH 03052022 May 17, 2022 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2022 Ended as of March 31, 2022 To: The President The Stock
with rules specified by the SEC Office. Clause 5 A derivatives broker shall not engage in any act which results in creating, altering, transferring, reserving or terminating a client’s right over assets